Paris — A new treatment for a drug-resistant strain of tuberculosis (TB) can cure 80% of sufferers, according to a trial hailed Monday as a “game changer” in the fight against the global killer. Doctors in Belarus — a country with one of the highest rates of multi-drug-resistant (MDR) TB in the world — spent months treating patients with a new drug, bedaquiline, alongside other antibiotics. The results, seen exclusively by AFP, are startling: of the 181 patients given the new drug, 168 people completed the course and 144 were totally cured. The World Health Organisation (WHO) says currently only 55% of people with MDR TB are successfully treated. The Belarus trial cure rate — 80% — was largely replicated in bedaquiline trials in other countries in eastern Europe, Africa and Southeast Asia, according to abstracts seen by AFP, due to be unveiled at a major TB conference later this week. “The results from this study confirm ... that newer drugs such as bedaquiline can cure and are game...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now